Humana Inc. Reports Q2 2026 Results: Detailed Investor Analysis
Key Financial Highlights
- GAAP Earnings Per Share (EPS): \$5.73 for Q2 2026, \$15.55 year-to-date.
- Adjusted EPS: \$7.61 for Q2 2026, \$17.91 year-to-date.
- GAAP Income Before Taxes: \$952 million for Q2 2026, \$2,547 million year-to-date.
- Adjusted Income Before Taxes: \$1,248 million for Q2 2026, \$2,918 million year-to-date.
- Insurance Segment GAAP Benefit Ratio: 91.2% for Q2 2026, in line with guidance; full-year guidance affirmed at 92.75% +/- 25 basis points.
- Full-Year 2026 Adjusted EPS Guidance: Affirmed at “at least \$9.00.”
- Full-Year 2026 GAAP EPS Guidance: Revised downward to “at least \$6.52” from previous “at least \$8.36.”
- Individual Medicare Advantage Membership Growth: Projected at “approximately 25%” for FY 2026, driven by new sales and improved retention.
Strategic and Operational Developments
- CenterWell Senior Primary Care: Year-to-date growth of 130,900 patients (27% increase).
- Medicaid Expansion: Humana awarded a statewide Illinois Medicaid managed care contract, expected to go live January 2027. Humana is the only new entrant, joining five incumbents.
- Prepared Management Remarks: Published ahead of the earnings call, reflecting management’s confidence in operational efficiency and clinical care improvements.
Detailed Financial Reconciliations and Adjustments
- Non-GAAP (Adjusted) financial measures exclude:
- Amortization associated with identifiable intangibles.
- Put/call valuation adjustments related to non-consolidating minority interest investments.
- Value creation initiatives (multi-year transformation program costs).
- Impairment charges (non-cash, minority ownership investments deemed unrecoverable).
- Cumulative net tax impact of above items.
- Additional FY 2025 GAAP EPS adjustments include:
- Impact of exit from employer group commercial medical products business.
- Settlement of certain litigation expenses.
- Loss on sale of business.
Management Commentary
“The first half of the year went well, and we’re right where we said we’d be at Investor Day last year,” said President and CEO Jim Rechtin. “When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve.”
Risks and Price-Sensitive Issues
- Revised GAAP EPS Guidance: The lowering of the full-year GAAP EPS guidance from \$8.36 to \$6.52 is a material development and may impact investor sentiment and share price.
- Medicare Star Ratings Headwind: Adjusted EPS is expected to decline year-over-year due to a significant reduction in the number of Medicare Advantage plans rated 4 stars or higher. Humana’s unsuccessful legal challenge to the 2025 Star Ratings could negatively affect 2026 quality bonus payments from CMS, revenues, operating results, and cash flows. Humana has appealed but there is no assurance of reversal.
- Regulatory and Litigation Risks: Humana faces substantial government regulation and ongoing legal actions, including provider contract disputes and qui tam litigation. These could result in monetary damages or changes to business practices, impacting costs and profitability.
- Risk Adjustment Model Changes: CMS’s Final RADV Rule could materially affect operating results, financial position, and cash flows if retrospective premium recovery or changes to risk-adjustment methodology are enforced.
- Strategic Expansion: The new Illinois Medicaid contract is a major growth opportunity, expanding Humana’s footprint in a key market.
- Operational Efficiency: Continued transformation initiatives signal focus on cost structure, operating model, and technology updates.
- Competition and Talent: Humana faces ongoing competition for talent and must manage succession for key executives. Failure here could impact performance.
- Pharmacy and Supply Chain Risks: The pharmacy business is highly competitive, subject to additional risks, and changes in prescription drug pricing benchmarks may affect performance.
- Debt Ratings and Market Volatility: Downgrades or disruptions in credit/securities markets may impact Humana’s investment portfolio and income.
Conference Call and Investor Information
- Humana hosted a Q2 2026 earnings webcast for analysts, with management remarks posted ahead of time.
- The archive of the webcast is available on Humana’s Investor Relations site.
- Investors are advised to review Humana’s SEC filings (Form 10-K for 2025, Form 10-Q for Q1 2026, and Form 8-Ks for 2026) for additional details on risks and historical performance.
About Humana
Humana (NYSE: HUM) is a leading U.S. healthcare company delivering insurance services and health care via its CenterWell brand. It serves millions across Medicare, Medicaid, families, individuals, military personnel, and communities, focusing on care quality and accessibility.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. All financial data and guidance are subject to change and involve risks and uncertainties as described in Humana’s SEC filings. Investors should independently review official filings and consult their financial advisors before making investment decisions. Past performance is not indicative of future results.
